Jinke Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinke Huang has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Fengyun Wang
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese, Medical Sciences, China
13 shared publications - Xudong Tang
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
13 shared publications - Jiaqi Zhang
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
6 shared publications - Jinxin Ma
Department of Gastroenterology, Peking University Traditional Chinese Medicine Clinical Medical School (Xiyuan), Beijing, China
6 shared publications - Yong Huang
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong Province, 510515, China
6 shared publications - Jing Ma
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
5 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22 (3) , 1618-1626
Effects of tai chi on balance function among stroke patients: a meta-analysis
Introduction: Impaired balance is a common and debilitating sequela among stroke survivors. Tai chi (TC), a traditional mind-body exercise, has emerged as a promising rehabilitative intervention. This meta-analysis aimed to quantitatively evaluate the effects of TC on balance function in post-stroke patients. Methods: A systematic literature search was conducted across eight electronic databases (PubMed, Embase, Web of Science, Cochrane Library, CNKI, SinoMed, VIP, and Wanfang Data) from their inception until May 13, 2025, to identify relevant randomized controlled trials (RCTs). Eligible studies compared TC (as an adjunct or standalone therapy) with conventional rehabilitation therapy (CRT) in stroke patients, using balance-related outcomes as endpoints. Methodological quality was assessed using the Cochrane Risk of Bias tool. Statistical synthesis was performed using RevMan software (version 5.4). Results: Twenty RCTs involving 1296 participants were included. The pooled results demonstrated that, compared to CRT alone, the integration of TC with CRT led to significantly greater improvements across multiple balance measures: the Berg Balance Scale (mean difference [MD] = 6.17, 95% confidence interval [CI]: 5.19 to 7.15), the Fugl-Meyer Assessment scale (MD = 7.18, 95% CI: 4.14 to 10.23), the Timed Up-and-Go test (MD = –2.03, 95% CI: –3.65 to –0.41), the Functional Reach Test (MD = 2.81, 95% CI: 0.29 to 5.33), the Modified Fall Efficacy Scale (MD = 8.70, 95% CI: 4.36 to 13.04), and the Fall Risk Index (MD = –0.78, 95% CI: –1.22 to –0.34). Conclusions: Current evidence suggests a beneficial effect of integrating TC with CRT for improving balance after stroke. However, due to methodological limitations and the overall quality of the included trials, these findings should be interpreted with caution. More rigorous and well-designed studies are needed before definitive clinical recommendations can be established.
- 3 June 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22 (3) , 1618-1626
Open AccessEffects of tai chi on balance function among stroke patients: a meta-analysis
Introduction: Impaired balance is a common and debilitating sequela among stroke survivors. Tai chi (TC), a traditional mind-body exercise, has emerged as a promising rehabilitative intervention. This meta-analysis aimed to quantitatively evaluate the effects of TC on balance function in post-stroke patients. Methods: A systematic literature search was conducted across eight electronic databases (PubMed, Embase, Web of Science, Cochrane Library, CNKI, SinoMed, VIP, and Wanfang Data) from their inception until May 13, 2025, to identify relevant randomized controlled trials (RCTs). Eligible studies compared TC (as an adjunct or standalone therapy) with conventional rehabilitation therapy (CRT) in stroke patients, using balance-related outcomes as endpoints. Methodological quality was assessed using the Cochrane Risk of Bias tool. Statistical synthesis was performed using RevMan software (version 5.4). Results: Twenty RCTs involving 1296 participants were included. The pooled results demonstrated that, compared to CRT alone, the integration of TC with CRT led to significantly greater improvements across multiple balance measures: the Berg Balance Scale (mean difference [MD] = 6.17, 95% confidence interval [CI]: 5.19 to 7.15), the Fugl-Meyer Assessment scale (MD = 7.18, 95% CI: 4.14 to 10.23), the Timed Up-and-Go test (MD = –2.03, 95% CI: –3.65 to –0.41), the Functional Reach Test (MD = 2.81, 95% CI: 0.29 to 5.33), the Modified Fall Efficacy Scale (MD = 8.70, 95% CI: 4.36 to 13.04), and the Fall Risk Index (MD = –0.78, 95% CI: –1.22 to –0.34). Conclusions: Current evidence suggests a beneficial effect of integrating TC with CRT for improving balance after stroke. However, due to methodological limitations and the overall quality of the included trials, these findings should be interpreted with caution. More rigorous and well-designed studies are needed before definitive clinical recommendations can be established.
- Open Access
- 21 January 2026
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2026 (1) , e6767725
Association Between Inflammatory Bowel Disease and Venous Leg Ulcers: Insight From Mendelian Randomization Analyses
Background: This study aimed to investigate the potential causal relationship between inflammatory bowel disease (IBD) and venous leg ulcers (VLU) using Mendelian randomization (MR). Materials and Methods: Independent genetic variants for IBD and VLU were selected as instruments from previously published genome‐wide association studies (GWAS) in people of primarily European descent. MR analyses were carried out utilizing inverse‐variance weighted (IVW), weighted median, MR Egger, simple mode, and weighted mode. Results: Genetically predicted IBD was not associated with VLU, according to the IVW analysis (OR 0.95, 95% CI 0.88–1.03, p = 0.23). MR Egger (OR 0.93, 95% CI 0.76–1.12, p = 0.44), weighted mode (OR 1.06, 95% CI 0.87–1.29, p = 0.55), simple mode (OR 1.03, 95% CI 0.79–1.34, p = 0.83), and weighted median (OR 0.99, 95% CI 0.89–1.10, p = 0.90) all produced results in line with IVW. According to the IVW technique, UC (OR 1.02, 95% CI 0.95–1.10, p = 0.62) and CD (OR 0.97, 95% CI 0.90–1.04, p = 0.36) did not appear to be associated with VLU in subtype analyses. Conclusion: The MR investigation found no genetic evidence to support a causal relationship between IBD and VLU. This finding clarifies that observed clinical associations are unlikely to be driven by shared genetics, and this genetic insight helps refine the clinical assessment of VLU in patients with IBD.
- 21 January 2026
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2026 (1) , e6767725
Open AccessAssociation Between Inflammatory Bowel Disease and Venous Leg Ulcers: Insight From Mendelian Randomization Analyses
Background: This study aimed to investigate the potential causal relationship between inflammatory bowel disease (IBD) and venous leg ulcers (VLU) using Mendelian randomization (MR). Materials and Methods: Independent genetic variants for IBD and VLU were selected as instruments from previously published genome‐wide association studies (GWAS) in people of primarily European descent. MR analyses were carried out utilizing inverse‐variance weighted (IVW), weighted median, MR Egger, simple mode, and weighted mode. Results: Genetically predicted IBD was not associated with VLU, according to the IVW analysis (OR 0.95, 95% CI 0.88–1.03, p = 0.23). MR Egger (OR 0.93, 95% CI 0.76–1.12, p = 0.44), weighted mode (OR 1.06, 95% CI 0.87–1.29, p = 0.55), simple mode (OR 1.03, 95% CI 0.79–1.34, p = 0.83), and weighted median (OR 0.99, 95% CI 0.89–1.10, p = 0.90) all produced results in line with IVW. According to the IVW technique, UC (OR 1.02, 95% CI 0.95–1.10, p = 0.62) and CD (OR 0.97, 95% CI 0.90–1.04, p = 0.36) did not appear to be associated with VLU in subtype analyses. Conclusion: The MR investigation found no genetic evidence to support a causal relationship between IBD and VLU. This finding clarifies that observed clinical associations are unlikely to be driven by shared genetics, and this genetic insight helps refine the clinical assessment of VLU in patients with IBD.
- Open Access
- 29 September 2025
- Published by Springer Nature in Systematic Reviews
- Vol. 14 (1) , 1-5
Efficacy and safety of fecal microbiota transplantation for ulcerative colitis: protocol for an umbrella review of systematic reviews
A growing number of systematic reviews and meta-analyses (SRs/MAs) based on randomized clinical trials have been carried out to assess the efficacy of fecal flora transplantation (FMT) in the treatment of ulcerative colitis (UC). An overview of SRs/MAs will be conducted with the aim of systematically compiling, evaluating, and synthesizing the evidence regarding FMT for UC. This is a protocol for an overview of SRs/MAs. We will search eight public electronic databases for the studies of FMT on UC. SRs/MAs of clinical trials evaluating the effect of FMT on UC will be included. Two independent authors will screen titles and abstracts retrieved in the literature search and select reviews meeting the eligibility criteria for full-text review. The methodological quality, reporting quality, and evidence quality of the included studies will be assessed, using, respectively, the AMSTAR-2 tool, PRISMA checklists, and GRADE system. From this study, the methodological quality, reporting quality, and evidence quality of the included SRs/MAs will be evaluated. We will also evaluate the efficacy of FMT in patients with UC. We will ascertain the efficacy of FMT in UC patients to provide evidence to guide the treatment of UC with FMT in the future. As a secondary study based on SRs/MAs, this study does not contain any individual patient information or violate participant rights. It is therefore not necessary to obtain ethics approval. We will report our findings in peer-reviewed journals or disseminate them at relevant conferences. Systematic review registration. PROSPERO CRD42023388682.
- 29 September 2025
- Published by Springer Nature in Systematic Reviews
- Vol. 14 (1) , 1-5
Open AccessEfficacy and safety of fecal microbiota transplantation for ulcerative colitis: protocol for an umbrella review of systematic reviews
A growing number of systematic reviews and meta-analyses (SRs/MAs) based on randomized clinical trials have been carried out to assess the efficacy of fecal flora transplantation (FMT) in the treatment of ulcerative colitis (UC). An overview of SRs/MAs will be conducted with the aim of systematically compiling, evaluating, and synthesizing the evidence regarding FMT for UC. This is a protocol for an overview of SRs/MAs. We will search eight public electronic databases for the studies of FMT on UC. SRs/MAs of clinical trials evaluating the effect of FMT on UC will be included. Two independent authors will screen titles and abstracts retrieved in the literature search and select reviews meeting the eligibility criteria for full-text review. The methodological quality, reporting quality, and evidence quality of the included studies will be assessed, using, respectively, the AMSTAR-2 tool, PRISMA checklists, and GRADE system. From this study, the methodological quality, reporting quality, and evidence quality of the included SRs/MAs will be evaluated. We will also evaluate the efficacy of FMT in patients with UC. We will ascertain the efficacy of FMT in UC patients to provide evidence to guide the treatment of UC with FMT in the future. As a secondary study based on SRs/MAs, this study does not contain any individual patient information or violate participant rights. It is therefore not necessary to obtain ethics approval. We will report our findings in peer-reviewed journals or disseminate them at relevant conferences. Systematic review registration. PROSPERO CRD42023388682.
- 28 July 2025
- Published by Oxford University Press (OUP) in Nutrition Reviews
- Vol. 84 (1) , 113-120
The Complementary and Alternative Roles of Curcumin in Treatment of Ulcerative Colitis: An Umbrella Review
Context: Evidence regarding curcumin supplementation in patients with ulcerative colitis (UC) has been inconsistent. Objective: This umbrella review aimed to summarize the effects of curcumin supplementation on UC and assess the strength of the evidence. Data Sources: A systematic search was conducted across the Cochrane Database of Systematic Reviews, PubMed, Web of Science, EMBASE, CNKI, Sino-Med, VIP, and Wanfang databases from their inception to June 9, 2024. Data extraction: Two review authors independently extracted data. Data Analysis: Methodological quality assessment, and evidence quality assessment, based on predetermined criteria, were performed by 2 independent reviewers. Seven systematic reviews and meta-analyses, encompassing 18 outcomes related to curcumin on UC, were included. Of these, 11 (77.78%) demonstrated statistical significance at the nominal level (P < .05). Conclusion: None of the reported outcomes were supported by high-certainty evidence, making the therapeutic potential of curcumin uncertain. Nevertheless, despite the widespread methodological shortcomings of the SRs/MAs, our study highlights opportunities to strengthen future research efforts. Umbrella review registration: PROSPERO registration No. CRD42024564400.
- 28 July 2025
- Published by Oxford University Press (OUP) in Nutrition Reviews
- Vol. 84 (1) , 113-120
The Complementary and Alternative Roles of Curcumin in Treatment of Ulcerative Colitis: An Umbrella Review
Context: Evidence regarding curcumin supplementation in patients with ulcerative colitis (UC) has been inconsistent. Objective: This umbrella review aimed to summarize the effects of curcumin supplementation on UC and assess the strength of the evidence. Data Sources: A systematic search was conducted across the Cochrane Database of Systematic Reviews, PubMed, Web of Science, EMBASE, CNKI, Sino-Med, VIP, and Wanfang databases from their inception to June 9, 2024. Data extraction: Two review authors independently extracted data. Data Analysis: Methodological quality assessment, and evidence quality assessment, based on predetermined criteria, were performed by 2 independent reviewers. Seven systematic reviews and meta-analyses, encompassing 18 outcomes related to curcumin on UC, were included. Of these, 11 (77.78%) demonstrated statistical significance at the nominal level (P < .05). Conclusion: None of the reported outcomes were supported by high-certainty evidence, making the therapeutic potential of curcumin uncertain. Nevertheless, despite the widespread methodological shortcomings of the SRs/MAs, our study highlights opportunities to strengthen future research efforts. Umbrella review registration: PROSPERO registration No. CRD42024564400.
- 18 March 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 346, 119643
Integrative investigation on the mechanisms of modified Zuojin pill (SQQT) in ameliorating gastric metaplasia
- 18 March 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 346, 119643
Integrative investigation on the mechanisms of modified Zuojin pill (SQQT) in ameliorating gastric metaplasia
- Open Access
- 16 January 2025
- Published by Wiley in Mediators of Inflammation
- Vol. 2025 (1) , 7468297
Modified Gegen Qinlian Decoction Ameliorates DSS‐Induced Colitis in Mice via the Modulation of NF‐ κ B and Nrf2/HO‐1 Pathways
Background: This study aims to reveal the potential molecular mechanisms of modified Gegen Qinlian decoction (MGQD) in relieving ulcerative colitis (UC). Methods: C57BL/6J mice were used to establish experimental colitis via dextran sodium sulfate (DSS). Body weight, disease activity index (DAI), spleen weight, colon length, and histopathologic features were measured to evaluate the therapeutic effects of MGQD on mice with UC. The ELISA kits were employed to assess the concentrations of interleukin (IL)‐6, IL‐1β, tumor necrosis factor‐α (TNF‐α), glutathione (GSH), reactive oxygen species (ROS), and malondialdehyde (MDA). Western blot analyses were used to assess the levels of IκBα, p65, p‐IκBα, p‐p65, HO‐1, and Nrf2. Moreover, the protein levels of Nrf2 and p‐p65 were assessed by immunofluorescence. Results: Colitis‐related symptoms in mice were significantly alleviated by MGQD. Moreover, MGQD inhibited the levels of TNF‐α, IL‐1β, IL‐6, MDA, and ROS and increased the level of GSH in mice with UC. Mechanistically, MGQD prevented the activation of the NF‐κB pathway and concomitantly promoted the activation of the Nrf2/HO‐1 pathway. Conclusion: MGQD alleviated UC by suppressing inflammation and oxidative stress via the modulation of NF‐κB and Nrf2/HO‐1 pathways, suggesting that MGQD may be a candidate therapy for UC.
- 16 January 2025
- Published by Wiley in Mediators of Inflammation
- Vol. 2025 (1) , 7468297
Open AccessModified Gegen Qinlian Decoction Ameliorates DSS‐Induced Colitis in Mice via the Modulation of NF‐ κ B and Nrf2/HO‐1 Pathways
Background: This study aims to reveal the potential molecular mechanisms of modified Gegen Qinlian decoction (MGQD) in relieving ulcerative colitis (UC). Methods: C57BL/6J mice were used to establish experimental colitis via dextran sodium sulfate (DSS). Body weight, disease activity index (DAI), spleen weight, colon length, and histopathologic features were measured to evaluate the therapeutic effects of MGQD on mice with UC. The ELISA kits were employed to assess the concentrations of interleukin (IL)‐6, IL‐1β, tumor necrosis factor‐α (TNF‐α), glutathione (GSH), reactive oxygen species (ROS), and malondialdehyde (MDA). Western blot analyses were used to assess the levels of IκBα, p65, p‐IκBα, p‐p65, HO‐1, and Nrf2. Moreover, the protein levels of Nrf2 and p‐p65 were assessed by immunofluorescence. Results: Colitis‐related symptoms in mice were significantly alleviated by MGQD. Moreover, MGQD inhibited the levels of TNF‐α, IL‐1β, IL‐6, MDA, and ROS and increased the level of GSH in mice with UC. Mechanistically, MGQD prevented the activation of the NF‐κB pathway and concomitantly promoted the activation of the Nrf2/HO‐1 pathway. Conclusion: MGQD alleviated UC by suppressing inflammation and oxidative stress via the modulation of NF‐κB and Nrf2/HO‐1 pathways, suggesting that MGQD may be a candidate therapy for UC.
- Open Access
- 16 July 2024
- Published by Springer Nature in Systematic Reviews
- Vol. 13 (1) , 1-5
Reliability of the evidence to guide decision-making in the treatment of gastroesophageal reflux disease with acupuncture: protocol for an overview of systematic reviews
Background: Growing numbers of randomized clinical trials-based systematic reviews and meta-analyses (SRs/MAs) have been conducted to examine the effectiveness of acupuncture in treating gastroesophageal reflux disease (GERD). An overview of SRs/MAs will be conducted with the aim of systematically compiling, evaluating, and synthesizing the evidence regarding acupuncture for GERD.Methods: SRs/MAs of acupuncture on GERD will be searched in eight databases. Two independent reviewers will conduct the literature search, data extraction, and review quality assessment. Utilizing the AMSTAR-2 tool, PRISMA checklists, and GRADE system, respectively, the methodological quality, reporting quality, and evidence quality will be evaluated. In relation to the subject and the overview’s objects, the results will be given. This study will aid in identifying gaps between evidence and its clinical application and serve as a roadmap for further high-quality research.Discussion: The results of the overview will aid in closing the gap between clinical evidence and its use in clinical practice. This study will identify significant faults in the use of evidence, point out areas where methodology needs to be improved, and provide guidance for future high-quality research.Systematic review registration: PROSPERO CRD42022371850.Ethics and dissemination: Ethics approval is not necessary because no personal information about individuals is collected. A peer-reviewed journal or pertinent conferences will publish the results, whichever comes first.
- 16 July 2024
- Published by Springer Nature in Systematic Reviews
- Vol. 13 (1) , 1-5
Open AccessReliability of the evidence to guide decision-making in the treatment of gastroesophageal reflux disease with acupuncture: protocol for an overview of systematic reviews
Background: Growing numbers of randomized clinical trials-based systematic reviews and meta-analyses (SRs/MAs) have been conducted to examine the effectiveness of acupuncture in treating gastroesophageal reflux disease (GERD). An overview of SRs/MAs will be conducted with the aim of systematically compiling, evaluating, and synthesizing the evidence regarding acupuncture for GERD.Methods: SRs/MAs of acupuncture on GERD will be searched in eight databases. Two independent reviewers will conduct the literature search, data extraction, and review quality assessment. Utilizing the AMSTAR-2 tool, PRISMA checklists, and GRADE system, respectively, the methodological quality, reporting quality, and evidence quality will be evaluated. In relation to the subject and the overview’s objects, the results will be given. This study will aid in identifying gaps between evidence and its clinical application and serve as a roadmap for further high-quality research.Discussion: The results of the overview will aid in closing the gap between clinical evidence and its use in clinical practice. This study will identify significant faults in the use of evidence, point out areas where methodology needs to be improved, and provide guidance for future high-quality research.Systematic review registration: PROSPERO CRD42022371850.Ethics and dissemination: Ethics approval is not necessary because no personal information about individuals is collected. A peer-reviewed journal or pertinent conferences will publish the results, whichever comes first.
- Open Access
- 7 February 2024
- Published by Wiley in Journal of Food Quality
- Vol. 2024, 1-14
Modified Gegen Qinlian Decoction Ameliorates DSS-Induced Ulcerative Colitis in Mice by Inhibiting Ferroptosis via Nrf2/GPX4 Pathway
Objective. Ferroptosis, a form of programmed cell death, is considered a novel target for the treatment of ulcerative colitis (UC). The aim of this study was to explore whether modified Gegen Qinlian decoction (MGQD) ameliorates UC in mice via mediating ferroptosis. Methods. Mice with dextran sulfate sodium- (DSS-) induced colitis were administered with MGQD for seven days. Subsequently, iron, malondialdehyde (MDA), glutathione (GSH), and reactive oxygen species (ROS) were measured. ELISA and immunohistochemistry were used to evaluate the levels of proinflammatory cytokines and tight junction proteins, respectively. Transmission electron microscopy was used to reveal mitochondrial morphology. Western blot and qRT-PCR analyses were used to assess the expression levels of the proteins of Nrf2/GPX4 pathway. The docking affinity of MGQD and Nrf2 was assessed using AutoDock Vina 1.1.2. Results. Ferroptosis was identified in mice with UC, as demonstrated by mitochondrial disruption, MDA and ROS production, iron overload, decrease in GSH level, and abnormal expression of core marker proteins of ferroptosis. After MGQD treatment, these characteristic changes of ferroptosis were significantly reversed, along with concomitant activation of the Nrf2/GPX4 pathway. Furthermore, molecular docking analysis revealed that MGQD had a high affinity for Nrf2. Conclusion. MGQD may ameliorate UC by inhibiting ferroptosis via the activation of Nrf2/GPX4 pathway. This study provided new insights into the application of MGQD complementary therapy for UC.
- 7 February 2024
- Published by Wiley in Journal of Food Quality
- Vol. 2024, 1-14
Open AccessModified Gegen Qinlian Decoction Ameliorates DSS-Induced Ulcerative Colitis in Mice by Inhibiting Ferroptosis via Nrf2/GPX4 Pathway
Objective. Ferroptosis, a form of programmed cell death, is considered a novel target for the treatment of ulcerative colitis (UC). The aim of this study was to explore whether modified Gegen Qinlian decoction (MGQD) ameliorates UC in mice via mediating ferroptosis. Methods. Mice with dextran sulfate sodium- (DSS-) induced colitis were administered with MGQD for seven days. Subsequently, iron, malondialdehyde (MDA), glutathione (GSH), and reactive oxygen species (ROS) were measured. ELISA and immunohistochemistry were used to evaluate the levels of proinflammatory cytokines and tight junction proteins, respectively. Transmission electron microscopy was used to reveal mitochondrial morphology. Western blot and qRT-PCR analyses were used to assess the expression levels of the proteins of Nrf2/GPX4 pathway. The docking affinity of MGQD and Nrf2 was assessed using AutoDock Vina 1.1.2. Results. Ferroptosis was identified in mice with UC, as demonstrated by mitochondrial disruption, MDA and ROS production, iron overload, decrease in GSH level, and abnormal expression of core marker proteins of ferroptosis. After MGQD treatment, these characteristic changes of ferroptosis were significantly reversed, along with concomitant activation of the Nrf2/GPX4 pathway. Furthermore, molecular docking analysis revealed that MGQD had a high affinity for Nrf2. Conclusion. MGQD may ameliorate UC by inhibiting ferroptosis via the activation of Nrf2/GPX4 pathway. This study provided new insights into the application of MGQD complementary therapy for UC.
- Open Access
- 31 January 2024
- Published by Wiley in Journal of Food Quality
- Vol. 2024, 1-12
Uncovering the Multitarget Therapeutic Mechanism of Tong-Xie-Yao-Fang on Irritable Bowel Syndrome
Background. This study investigated the pharmacological mechanisms of Tong-Xie-Yao-Fang (TXYF) against irritable bowel syndrome (IBS). Methods. The chemical profile of TXYF was identified through UHPLC-QTOF-MS. Next, the obtained chemical profile served as the basis for network pharmacological analysis. Finally, the predictive performance of network pharmacology was validated by conducting molecular docking and animal experiment. Results. Seven key compounds of TXYF, namely, quercetin, ellagic acid, nobiletin, formononetin, isorhamnetin, vestitol, and licochalcone, were confirmed as the key components acting on IBS. TXYF treatment on IBS was mainly realized through the regulation of some key pathways of immune system, such as inflammatory bowel disease, cytokine-cytokine receptor interaction, HIF-1, and T cell receptor signaling pathway. NOS2, ACHE, ESR1, PTGS2, and RELA were the target genes of TXYF to improve IBS. Stable bonds between the key components and the core target genes were further verified by the results of molecular docking. In vivo experiments confirmed the effects of TXYF on IBS. Further Western blot analysis showed that NOS2, ACHE, and ERα were significantly upregulated in the model group in comparison with controls ( ) but then significantly downregulated after treatment with TXYF for 14 days ( ). Conclusion. This study applied an integrated method based on network pharmacology and experimental validation to examine the underlying “multicomponent, multitarget, and multipathway” mode of action of TXYF in treating IBS. The current findings provided indicative paradigms and new insights into exploring the multitarget therapeutic mechanism of Chinese herbal compound.
- 31 January 2024
- Published by Wiley in Journal of Food Quality
- Vol. 2024, 1-12
Open AccessUncovering the Multitarget Therapeutic Mechanism of Tong-Xie-Yao-Fang on Irritable Bowel Syndrome
Background. This study investigated the pharmacological mechanisms of Tong-Xie-Yao-Fang (TXYF) against irritable bowel syndrome (IBS). Methods. The chemical profile of TXYF was identified through UHPLC-QTOF-MS. Next, the obtained chemical profile served as the basis for network pharmacological analysis. Finally, the predictive performance of network pharmacology was validated by conducting molecular docking and animal experiment. Results. Seven key compounds of TXYF, namely, quercetin, ellagic acid, nobiletin, formononetin, isorhamnetin, vestitol, and licochalcone, were confirmed as the key components acting on IBS. TXYF treatment on IBS was mainly realized through the regulation of some key pathways of immune system, such as inflammatory bowel disease, cytokine-cytokine receptor interaction, HIF-1, and T cell receptor signaling pathway. NOS2, ACHE, ESR1, PTGS2, and RELA were the target genes of TXYF to improve IBS. Stable bonds between the key components and the core target genes were further verified by the results of molecular docking. In vivo experiments confirmed the effects of TXYF on IBS. Further Western blot analysis showed that NOS2, ACHE, and ERα were significantly upregulated in the model group in comparison with controls ( ) but then significantly downregulated after treatment with TXYF for 14 days ( ). Conclusion. This study applied an integrated method based on network pharmacology and experimental validation to examine the underlying “multicomponent, multitarget, and multipathway” mode of action of TXYF in treating IBS. The current findings provided indicative paradigms and new insights into exploring the multitarget therapeutic mechanism of Chinese herbal compound.